Krystal Biotech (KRYS)
Commercializes VYJUVEK and develops redosable genetic medicines across multiple organ systems.
$340.29
vs last close−10.59 (−3.02%)
Something off on this page? Send us feedback.
Next report
Nov 2, 26
in 40 days
EPS estimate
$1.91
Revenue estimate
$129.6M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$1.52$1.20$1.29$2.66$1.70$1.83$1.79Pending
Estimate$1.29$1.38$1.08$1.12$1.62$1.45$1.70$1.91
Surprise+17.8%−13.0%+19.4%+137.5%+4.9%+26.2%+5.3%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$91.1M$88.2M$96.0M$97.8M$107.1M$116.4M$119.2MPending
Estimate$91.4M$106.0M$95.4M$105.3M$105.3M$112.1M$120.9M$129.6M
Surprise−0.2%−16.8%+0.7%−7.1%+1.7%+3.8%−1.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $2.79 | — | — |
| Sep 2027 | $2.47 | — | — |
| Jun 2027 | $2.25 | — | — |
| Mar 2027 | $2.23 | — | — |
| Dec 2026 | $2.11 | — | — |
| Nov 2026 | $1.91 | — | — |
| Aug 2026 | $1.70 | $1.79 | +5.3% |
| May 2026 | $1.45 | $1.83 | +26.2% |
| Feb 2026 | $1.62 | $1.70 | +4.9% |
| Nov 2025 | $1.12 | $2.66 | +137.5% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Jun 2017 | |||
| Sep 2017 | |||
| Dec 2016 | |||
| Sep 2016 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $2.79 | — | — | $185.9M | — | — | — |
| Sep 2027 | $2.47 | — | — | $169.4M | — | — | — |
| Jun 2027 | $2.25 | — | — | $153.5M | — | — | — |
| Mar 2027 | $2.23 | — | — | $143.4M | — | — | — |
| Dec 2026 | $2.11 | — | — | $142.9M | — | — | — |
| Nov 2, 2026 | $1.91 | — | — | $129.6M | — | — | — |
| Aug 3, 2026 | $1.70 | $1.79 | +5.3% | $120.9M | $119.2M | −1.4% | −8.4% |
| May 4, 2026 | $1.45 | $1.83 | +26.2% | $112.1M | $116.4M | +3.8% | +7.9% |
| Feb 17, 2026 | $1.62 | $1.70 | +4.9% | $105.3M | $107.1M | +1.7% | +4.1% |
| Nov 3, 2025 | $1.12 | $2.66 | +137.5% | $105.3M | $97.8M | −7.1% | +0.2% |
| Aug 4, 2025 | |||||||
| May 6, 2025 | |||||||
| Feb 19, 2025 | |||||||
| Nov 4, 2024 | |||||||
| Aug 5, 2024 | |||||||
| May 6, 2024 | |||||||
| Feb 26, 2024 | |||||||
| Nov 6, 2023 | |||||||
| Aug 7, 2023 | |||||||
| May 8, 2023 | |||||||
| Feb 27, 2023 | |||||||
| Nov 7, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 9, 2022 | |||||||
| Feb 28, 2022 | |||||||
| Nov 8, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 10, 2021 | |||||||
| Mar 1, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 4, 2020 | |||||||
| Mar 10, 2020 | |||||||
| Nov 4, 2019 | |||||||
| Aug 5, 2019 | |||||||
| May 7, 2019 | |||||||
| Mar 12, 2019 | |||||||
| Nov 5, 2018 | |||||||
| Aug 6, 2018 | |||||||
| May 7, 2018 | |||||||
| Mar 12, 2018 | |||||||
| Nov 13, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Sep 20, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Sep 30, 2016 |